Nanogami

Nanogami

Munich, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Nanogami is pioneering a horizontal biochip framework using DNA origami to precisely place sensor molecules and signal-amplifying nanostructures at scale. Its technology platform targets the core challenges of biochip performance—throughput, sensitivity, specificity, and cost—across genomics, transcriptomics, and proteomics applications. As a private, early-stage platform company, Nanogami is seeking industry partners to collaborate on developing customized biochips, positioning itself as an enabler for the broader life sciences and diagnostics industry.

Genetics & Genomics

Technology Platform

Proprietary DNA origami technology to create nanostructured breadboards that precisely place sensor molecules and signal-amplifying features for integration into ultra-high-density, customizable biochips.

Opportunities

The platform addresses the multi-billion dollar biochip and NGS markets by solving core performance limitations.
Its horizontal, customizable nature allows it to serve multiple applications (genomics, proteomics, diagnostics) simultaneously, creating a broad addressable market.

Risk Factors

Key risks include the technical challenge of scaling DNA origami fabrication industrially, the commercial hurdle of displacing entrenched biochip technologies, and the execution risk of a horizontal platform strategy requiring diverse partnerships.

Competitive Landscape

Competitors include established providers of microarray and biochip surfaces (e.g., Illumina, Thermo Fisher, Agilent) and other DNA nanotechnology startups. Nanogami differentiates by combining single-molecule placement precision with integrated signal amplification and a focus on a customizable, industry-spanning framework rather than a single product.